bdf 9148 has been researched along with dobutamine in 2 studies
| Studies (bdf 9148) | Trials (bdf 9148) | Recent Studies (post-2010) (bdf 9148) | Studies (dobutamine) | Trials (dobutamine) | Recent Studies (post-2010) (dobutamine) |
|---|---|---|---|---|---|
| 39 | 0 | 1 | 6,357 | 818 | 1,011 |
| Protein | Taxonomy | bdf 9148 (IC50) | dobutamine (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 4.17 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 5.551 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 5.519 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 3.975 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 1.517 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.383 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 1.944 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.599 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 2.966 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.383 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.114 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 1.895 | |
| D(3) dopamine receptor | Homo sapiens (human) | 4.985 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.155 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.518 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gill, RM; Jones, BD; Shen, W; Steinberg, MI | 1 |
| Corbly, AK; Gill, RM; Jones, BD; Shen, W; Steinberg, MI; Zhang, JP | 1 |
2 other study(ies) available for bdf 9148 and dobutamine
| Article | Year |
|---|---|
A sodium channel enhancer, LY341311, increases myocardial contractile performance without increasing heart rate in conscious normal dogs: a comparison with dobutamine.
Topics: Animals; Azetidines; Cardiotonic Agents; Consciousness; Dobutamine; Dogs; Heart Rate; Hemodynamics; Male; Myocardial Contraction; Sodium Channels | 2002 |
Combined inotropic and bradycardic effects of a sodium channel enhancer in conscious dogs with heart failure: a mechanism for improved myocardial efficiency compared with dobutamine.
Topics: Animals; Azetidines; Cardiotonic Agents; Chronic Disease; Coronary Circulation; Cyclic AMP; Dobutamine; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Heart Failure; Heart Rate; Male; Myocardial Contraction; Myocardium; Oxygen Consumption; Sodium Channel Agonists; Ventricular Function, Left | 2002 |